Abstract: A cryocooler includes a displacer that includes a lid portion and a main body portion, a displacer drive shaft that includes a collar portion held between the lid portion and the main body portion, and a buffer that is disposed in a clearance between the collar portion and the lid portion or between the collar portion and the main body portion and includes a soft material and a hard material disposed on an opposite side to the collar portion with respect to the soft material.

Abstract: A cryocooler includes a displacer that includes a lid portion and a main body portion, a displacer drive shaft that includes a collar portion held between the lid portion and the main body portion, and a buffer that is disposed in a clearance between the collar portion and the lid portion or between the collar portion and the main body portion and includes a soft material and a hard material disposed on an opposite side to the collar portion with respect to the soft material.

Abstract: A cryocooler includes a second-stage cooling stage, a second cylinder which includes the second-stage cooling stage on a terminal of the second-stage cylinder, a second-stage displacer which includes a magnetic regenerator material and is accommodated in the second-stage cylinder so as to be able to reciprocate in the second-stage cylinder, and a tubular magnetic shield which is installed on the second-stage cooling stage and extends along the second-stage cylinder outside the second-stage cylinder. The magnetic shield is formed of a normal conductor and a product of an electrical conductivity in a temperature range of 10 K (Kelvin) or less and a thickness of the tubular magnetic shield is 60 MS (Mega-Siemens) to 1980 MS.

Abstract: The present invention provides an industrially advantageous method for producing a 3,5-disubstituted triazine compound that is useful as an active pharmaceutical ingredient. More specifically, the present invention provides a production method, whereby it becomes possible to efficiently produce a 3-oxo-5-substituted triazine in water without the need to isolate an intermediate that may have mutagenicity, and it also becomes possible to perform the production without the need to isolate a product in each of multiple steps. Namely, the present invention provides a method for producing a compound represented by formula I or a salt thereof, the method including a step of reacting a compound represented by the following formula IV or a salt thereof with a base in water, and optionally including a step of forming a salt thereof.

Abstract: A cryocooler includes a second-stage cooling stage, a second cylinder which includes the second-stage cooling stage on a terminal of the second-stage cylinder, a second-stage displacer which includes a magnetic regenerator material and is accommodated in the second-stage cylinder so as to be able to reciprocate in the second-stage cylinder, and a tubular magnetic shield which is installed on the second-stage cooling stage and extends along the second-stage cylinder outside the second-stage cylinder. The magnetic shield is formed of a normal conductor and a product of an electrical conductivity in a temperature range of 10 K (Kelvin) or less and a thickness of the tubular magnetic shield is 60 MS (Mega-Siemens) to 1980 MS.

Abstract: The present invention provides an industrially advantageous method for producing a 3,5-disubstituted triazine compound that is useful as an active pharmaceutical ingredient. More specifically, the present invention provides a production method, whereby it becomes possible to efficiently produce a 3-oxo-5-substituted triazine in water without the need to isolate an intermediate that may have mutagenicity, and it also becomes possible to perform the production without the need to isolate a product in each of multiple steps. Namely, the present invention provides a method for producing a compound represented by formula I or a salt thereof, the method including a step of reacting a compound represented by the following formula IV or a salt thereof with a base in water, and optionally including a step of forming a salt thereof.

Abstract: A cryocooler includes a second-stage cooling stage, a second cylinder which includes the second-stage cooling stage on a terminal of the second-stage cylinder, a second-stage displacer which includes a magnetic regenerator material and is accommodated in the second-stage cylinder so as to be able to reciprocate in the second-stage cylinder, and a tubular magnetic shield which is installed on the second-stage cooling stage and extends along the second-stage cylinder outside the second-stage cylinder. The magnetic shield is formed of a normal conductor and a product of an electrical conductivity in a temperature range of 10 K (Kelvin) or less and a thickness of the tubular magnetic shield is 60 MS (Mega-Siemens) to 1980 MS.

Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.

Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.

Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.